Lantheus (NASDAQ:LNTH) Updates Q2 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its second quarter earnings guidance on Thursday morning. The company provided EPS guidance of $1.81-1.86 for the period, compared to the consensus EPS estimate of $1.66. The company issued revenue guidance of $380-390 million, compared to the consensus revenue estimate of $356.88 million. Lantheus also updated its FY24 guidance to $7.00-7.20 EPS.

Analysts Set New Price Targets

LNTH has been the subject of several recent research reports. StockNews.com downgraded Lantheus from a buy rating to a hold rating in a report on Friday. JMP Securities reaffirmed a market outperform rating and issued a $100.00 price objective on shares of Lantheus in a research report on Friday, February 23rd. Truist Financial upped their target price on shares of Lantheus from $82.00 to $96.00 and gave the company a buy rating in a research note on Friday. B. Riley upped their price objective on shares of Lantheus from $95.00 to $99.00 and gave the company a buy rating in a research report on Thursday, April 18th. Finally, Mizuho increased their price target on Lantheus from $90.00 to $100.00 and gave the company a buy rating in a report on Friday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $103.14.

Lantheus Stock Performance

NASDAQ:LNTH traded down $2.65 during trading hours on Friday, reaching $75.53. 1,838,111 shares of the stock were exchanged, compared to its average volume of 909,698. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85. The company has a quick ratio of 5.45, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $5.18 billion, a P/E ratio of 11.53 and a beta of 0.52. The firm has a 50 day simple moving average of $62.67 and a 200-day simple moving average of $62.76.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. As a group, sell-side analysts forecast that Lantheus will post 5.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold a total of 94,545 shares of company stock worth $6,169,936 over the last quarter. 1.50% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.